The 8 Wall Street analysts covering Lumexa Imaging Holdings, Inc. hold a median 12-month price target of $17 — +59.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lumexa Imaging Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (53): Analysts have, on balance, been raising their forecasts.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LMRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +59.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | Barclays | Maintains | Overweight | $9.00 → $13 |
| 20 May 2026 | Barclays | Maintains | Overweight | — |
| 20 May 2026 | Barclays | Maintains | Overweight | $15 → $9.00 |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 9 Feb 2026 | Raymond James | Upgrade | Strong Buy | — |
| 5 Jan 2026 | Barclays | Initiates | Overweight | — |
| 5 Jan 2026 | Deutsche Bank | Initiates | Buy | — |
| 5 Jan 2026 | Jefferies | Initiates | Buy | — |
| 5 Jan 2026 | Leerink Partners | Initiates | Outperform | — |
| 5 Jan 2026 | Raymond James | Initiates | Outperform | — |
| 5 Jan 2026 | Wells Fargo | Initiates | Overweight | — |
| 5 Jan 2026 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LMRI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 69% of US stocks
Cheaper than 50% of US stocks
Cheaper than 11% of US stocks
Higher than 39% of US stocks
Higher than 45% of US stocks
Higher than 14% of US stocks
Higher than 51% of US stocks
Higher than 27% of US stocks
Higher than 37% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lumexa Imaging Holdings, Inc. has a market value of $1.1B and an enterprise value of $2.0B.
Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 5.1% year on year.
Net income over the same four quarters: −$27.7M, a −2.7% net margin.
Free cash flow in the twelve months to 30 June 2026: $31.2M.
Trailing P/E: −16.8×; forward P/E: 12.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Lumexa Imaging Holdings, Inc. employs 5,000 people — $209K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lumexa Imaging Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research upgraded Lumexa Imaging Holdings, Inc. (LMRI) to a Zacks Rank #2 (Buy), citing growing optimism about its earnings prospects. The upgrade reflects a more favorable outlook for the company's near-term performance.
Why it matters — A Zacks upgrade to Buy signals improving expectations for LMRI's earnings, which an investor tracking the stock would want to note.
Lumexa Imaging Holdings announced that CEO Caitlin Zulla and CFO Tony Martin will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026, including a fireside chat and one-on-one meetings.
Why it matters — The company's leadership participating in a major healthcare investor conference offers Lumexa Imaging shareholders visibility into the company and engagement with the investment community.
Wall Street analysts' consensus price target implies a roughly 36.9% upside potential for Lumexa (LMRI), though the article notes this metric is not highly effective. It also points to an upward trend in earnings estimate revisions as a possible near-term positive signal for the stock.
Why it matters — A Lumexa watcher would care because the analyst consensus target and upward earnings estimate revisions point to possible upside for the stock in the near term.
Lumexa Imaging Holdings, Inc. (LMRI) held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The brief item indicates the earnings call transcript is now available to readers.
Why it matters — A LMRI watcher would care because the earnings call transcript provides direct insight into the company's Q2 2026 results and management commentary.
Lumexa Imaging reported second-quarter revenue growth, higher advanced-imaging volumes, and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reaffirming its revenue and adjusted EPS guidance.
Why it matters — The return to profitability and narrowed EBITDA outlook signal improved financial discipline, while the reaffirmed guidance offers LMRI watchers a steady view of the company's near-term expectations.
The 8 Wall Street analysts covering Lumexa Imaging Holdings, Inc. have a median 12-month price target of $17, with estimates ranging from $13 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Lumexa Imaging Holdings, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lumexa Imaging Holdings, Inc. 1 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Lumexa Imaging Holdings, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (53 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +59.2% from the last close, and Ticker Nerd's factor model ranks Lumexa Imaging Holdings, Inc. 1 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lumexa Imaging Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LMRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $23 over the next 12 months.
Lumexa Imaging Holdings, Inc. is a U.S.
The most recent item we track (Zacks Investment Research, 15 Sept 2026): "Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know". Zacks Investment Research upgraded Lumexa Imaging Holdings, Inc. (LMRI) to a Zacks Rank #2 (Buy), citing growing optimism about its earnings prospects. The upgrade reflects a more favorable outlook for the company's near-term performance.
Lumexa Imaging Holdings, Inc. is a U.S. diagnostic imaging services company that owns and operates outpatient imaging centers across multiple states. Lumexa Imaging provides a broad range of medical imaging and screening services, including MRI, CT, PET, X-ray, ultrasound, and mammography, supporting the diagnosis and monitoring of a wide variety of conditions. The company also offers professional interpretation services for imaging studies through its radiology-focused operations and teleradiology platform. Its business is organized around outpatient imaging centers and professional services, allowing it to serve patients, referring physicians, health systems, and other care providers. Based in Raleigh, North Carolina, Lumexa Imaging plays a meaningful role in expanding access to noninvasive diagnostic services within the U.S. health care market.
CEO Ms. Caitlin Zulla · 5,000 employees · United States · https://www.lumexaimaging.com
